Roswell Park Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Roswell Park Cancer Institute sits in the top decile of US sponsors by registered trial count (#98 of 15,742 sponsors by registered trial count).
Roswell Park Cancer Institute: 365 sponsored US clinical trials, 57 recruiting.
Roswell Park Cancer Institute sponsors 365 registered US clinical trials on ClinicalTrials.gov, 57 of them currently recruiting, and 200 completed. 7 of these trials are in Phase 3-4 (later-stage) and 238 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Leukemia, with 9 trials.
Top-decile sponsor footprint
Roswell Park Cancer Institute ranks in the top decile of sponsors by registered trial count (#98 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
200 of 279 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
365 total, page 5 of 8
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01529827
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
NCT01174199
Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery
NCT01527136
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
NCT01533948
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01527149
Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy
NCT01521936
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
NCT01555268
Cholecalciferol and Flu Vaccine in Treating Healthy Participants
NCT01561989
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
NCT01564277
Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
NCT01093092
Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers
NCT01800500
Bathing Bundle Regimen in Reducing Gynecological Surgical Site Infection in Patients Undergoing Surgery
NCT01597804
Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer
NCT01292668
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01246622
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
NCT01178944
High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer
NCT01198548
A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx
NCT01140178
Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer
NCT00670397
Guided Biopsy for Mapping Prostate Cancer
NCT01007214
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery
NCT01108003
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
NCT01014546
Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia
NCT01236417
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
NCT01582009
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
NCT01061411
Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage
NCT01038024
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
NCT01649791
Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
NCT01027416
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
NCT01007552
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
NCT01032148
Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities
NCT02100254
Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
NCT01003678
Brody Belt - Alternative Method of Securing a Patient's Urinary Drainage Bag
NCT01228864
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
NCT00970203
Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
NCT01004159
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
NCT00981162
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
NCT00942266
Acceptability of Less Harmful Alternatives to Cigarettes
NCT00957424
Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
NCT01682031
Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation
NCT00887432
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
NCT01673217
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
NCT00891904
An Alternative Dosing Schedule of Varenicline for Smoking Cessation
NCT00835900
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
NCT00856388
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
NCT00851552
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00814164
Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
NCT00843726
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
NCT00736645
Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer
NCT00690924
Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery
NCT00732563
Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
NCT00683787
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 123 |
| Phase 2 | 115 |
| Phase 3 | 5 |
| Phase 4 | 2 |
What is open in the Roswell Park Cancer Institute pipeline
57 recruiting of 365 indexed (16% open); 200 completed (55%).
Phase mix: 7 late (III/IV) vs 238 early (I/II) (early-phase heavy).
Top condition: Leukemia (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Roswell Park Cancer Institute: open-pipeline peers nationwide
Peers matched on 365 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
Roswell Park Cancer Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 365 trials (± recruiting share)
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Cambridge Health Alliance · 16% recruiting · 45 trials
- Louisiana State University Health Sciences Center in New Orleans · 16% recruiting · 45 trials
- University of Southern California · 16% recruiting · 617 trials
- Incyte Corporation · 15% recruiting · 239 trials
Related
What to do with this Roswell Park Cancer Institute page
365 registered trials is a research-attention snapshot, not an endorsement of Roswell Park Cancer Institute or any single study.
- 57 of Roswell Park Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Leukemia is the condition Roswell Park Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Roswell Park Cancer Institute pipeline card: 365 registered trials from official public datasets.Report a data error.